Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models

The Monte Carlo Parametric Expectation Maximization (MC-PEM) algorithm can approximate the true log-likelihood as precisely as needed and is efficiently parallelizable. Our objectives were to evaluate an importance sampling version of the MC-PEM algorithm for mechanistic models and to qualify the default estimation settings in SADAPT-TRAN. We assessed bias, imprecision and robustness of this algorithm in S-ADAPT for mechanistic models with up to 45 simultaneously estimated structural parameters, 14 differential equations, and 10 dependent variables (one drug concentration and nine pharmacodynamic effects). Simpler models comprising 15 parameters were estimated using three of the ten dependent variables. We set initial estimates to 0.1 or 10 times the true value and evaluated 30 bootstrap replicates with frequent or sparse sampling. Datasets comprised three dose levels with 16 subjects each. For simultaneous estimation of the full model, the ratio of estimated to true values for structural model parameters (median [5–95% percentile] over 45 parameters) was 1.01 [0.94–1.13] for means and 0.99 [0.68–1.39] for between-subject variances for frequent sampling and 1.02 [0.81–1.47] for means and 1.02 [0.47–2.56] for variances for sparse sampling. Imprecision was ≤25% for 43 of 45 means for frequent sampling. Bias and imprecision was well comparable for the full and simpler models. Parallelized estimation was 23-fold (6.9-fold) faster using 48 threads (eight threads) relative to one thread. The MC-PEM algorithm was robust and provided unbiased and adequately precise means and variances during simultaneous estimation of complex, mechanistic models in a 45 dimensional parameter space with rich or sparse data using poor initial estimates.

[1]  W. Jusko,et al.  Note: Caution in Use of Empirical Equations for Pharmacodynamic Indirect Response Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  Jelliffe Rw The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. , 1991 .

[3]  Lewis B. Sheiner,et al.  Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.

[4]  A. Schumitzky Nonparametric EM Algorithms for estimating prior distributions , 1991 .

[5]  Mats O. Karlsson,et al.  Performance in population models for count data, part I: maximum likelihood approximations , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  É. Moulines,et al.  Convergence of a stochastic approximation version of the EM algorithm , 1999 .

[7]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.

[8]  Lewis B. Sheiner,et al.  Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[9]  S. Ait-Oudhia,et al.  Simultaneous Pharmacokinetics/Pharmacodynamics Modeling of Recombinant Human Erythropoietin upon Multiple Intravenous Dosing in Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.

[10]  D. DuBois,et al.  Mechanism-Based Modeling of Nutritional and Leptin Influences on Growth in Normal and Type 2 Diabetic Rats , 2009, Journal of Pharmacology and Experimental Therapeutics.

[11]  D J Roe Comparison of population pharmacokinetic modeling methods using simulated data: results from the Population Modeling Workgroup. , 1997, Statistics in medicine.

[12]  A. Joshi,et al.  Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis , 2005, Pharmaceutical Research.

[13]  Ss Beal,et al.  NONMEM User’s Guides. (1989–2009) , 2009 .

[14]  L. Petzold Automatic Selection of Methods for Solving Stiff and Nonstiff Systems of Ordinary Differential Equations , 1983 .

[15]  D. Rubin,et al.  Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper , 1977 .

[16]  Robert J. Bauer,et al.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples , 2007, The AAPS Journal.

[17]  A. Tolcher,et al.  Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients , 2009, Cancer Chemotherapy and Pharmacology.

[18]  T. Wajima,et al.  A Comprehensive Model for the Humoral Coagulation Network in Humans , 2009, Clinical pharmacology and therapeutics.

[19]  Mats O. Karlsson,et al.  Mechanistic Models for Myelosuppression , 2003, Investigational New Drugs.

[20]  Richard R. Almon,et al.  Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[21]  Alan Schumitzky,et al.  Model-Based, Goal-Oriented, Individualised Drug Therapy , 1998, Clinical pharmacokinetics.

[22]  Stephen G Walker,et al.  AN EM ALGORITHM FOR NONLINEAR RANDOM EFFECTS MODELS , 1996 .

[23]  N. Laird Nonparametric Maximum Likelihood Estimation of a Mixing Distribution , 1978 .

[24]  W. Jusko,et al.  Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients , 2009, Cancer Chemotherapy and Pharmacology.

[25]  Richard R Almon,et al.  Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced Arthritis , 2008, Journal of Pharmacology and Experimental Therapeutics.

[26]  Robert Leary,et al.  Parametric and Nonparametric Population Methods , 2006, Clinical pharmacokinetics.

[27]  Wojciech Krzyzanski,et al.  Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations , 2009, Clinical pharmacokinetics.

[28]  R W Jelliffe The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. , 1991, Proceedings. Symposium on Computer Applications in Medical Care.

[29]  Neang S. Ly,et al.  Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.

[30]  Mats O. Karlsson,et al.  Nonlinearity detection: Advantages of nonlinear mixed-effects modeling , 2000, AAPS PharmSci.

[31]  C. Takimoto,et al.  Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients , 2011, Cancer Chemotherapy and Pharmacology.

[32]  New York Dover,et al.  ON THE CONVERGENCE PROPERTIES OF THE EM ALGORITHM , 1983 .

[33]  E. Kuhn,et al.  Coupling a stochastic approximation version of EM with an MCMC procedure , 2004 .

[34]  H. Fung,et al.  Pharmacokinetics of 1,4-Butanediol in Rats: Bioactivation to γ-Hydroxybutyric Acid, Interaction with Ethanol, and Oral Bioavailability , 2008, The AAPS Journal.

[35]  Eric Moulines Convergence of a stochastic approximation version of the EMalgorithmMarc Lavielle , 1997 .

[36]  Donald E Mager,et al.  Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients , 2008, Journal of Pharmacology and Experimental Therapeutics.

[37]  J F Boisvieux,et al.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. , 1984, Drug metabolism reviews.

[38]  Xiaoning Wang,et al.  Nonlinear random effects mixture models: Maximum likelihood estimation via the EM algorithm , 2007, Comput. Stat. Data Anal..

[39]  Wojciech Krzyzanski,et al.  Indirect Pharmacodynamic Models for Responses with Multicompartmental Distribution or Polyexponential Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[40]  DE Mager,et al.  Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.

[41]  D. Lalloo,et al.  A model for venom-induced consumptive coagulopathy in snake bite. , 2008, Toxicon : official journal of the International Society on Toxinology.

[42]  J. Verweij,et al.  Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements , 2008, Clinical pharmacology and therapeutics.

[43]  Stuart L. Beal,et al.  Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[44]  Stephen B Duffull,et al.  ANALYSIS OF POPULATION PHARMACOKINETIC DATA USING NONMEM AND WinBUGS , 2004, Journal of biopharmaceutical statistics.

[45]  Siv Jönsson,et al.  Estimating Bias in Population Parameters for Some Models for Repeated Measures Ordinal Data Using NONMEM and NLMIXED , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[46]  David Z. D'Argenio,et al.  Physiologically-Based Pharmacokinetics and Molecular Pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and Its Active Metabolite in Tumor-Bearing Mice , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[47]  Robert J. Bauer,et al.  Monte Carlo Parametric Expectation Maximization (MC-PEM) Method for Analyzing Population Pharmacokinetic/Pharmacodynamic Data , 2004 .

[48]  David Z. D'Argenio,et al.  Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis , 2004, Springer US.

[49]  Alan E. Gelfand,et al.  Bayesian statistics without tears: A sampling-resampling perspective , 1992 .

[50]  Neang S. Ly,et al.  Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model , 2010, Antimicrobial Agents and Chemotherapy.